NeuLogiq® Platform

CUMULUS NEUROSCIENCE

Designed for Use in Clinical Trials with Top 10 Pharma Advisory Group, the NeuLogiq Platform provides frequent, reliable in-clinic and at-home longitudinal monitoring of discrete brain functions.

Tablet Based Assessment

Designed for Patients

Easy-to-use measurement tools that patients want to engage with.

Study Management Hub

Built for Researchers

Reliable, repeatable and scalable brain function data you can trust.

Tablet Based Assessment

Made for Real-World Studies

Engaging multi-modal assessments for use in clinic or at home, unified in one platform.

Repeated Measures

Easy-to-use platform combining low patient burden with high reliability and patient adherence.

Multi-Modal Insights

Incorporate data from multiple modalities such as cognition, EEG, mood, language and sleep powered by Muse®

Full Analysis Pipeline

Built on our reproducible, reliable analysis pipeline using advanced signal processing and machine learning to characterize EEG signals.

Cognition

Tablet-based cognitive assessments designed for repeated, real-world use.

EEG

Neurophysiological measurements capturing brain network activity, synchronised with behavioural data.

Mood

EMA (self-reported),
questionnaires.

Speech

Speech rate, output,
pausing behavior.

NeuLogiq Sleep
powered by Muse®

The Muse S Athena is a comfortable, easy to use at-home EEG wearable validated against Level 1 polysomnography.

EEG Headset

UKCA-marked and FDA 510(k) cleared medical device, combining regulatory compliance with award-winning design for clinical and research EEG applications.

EEG Headset

NeuLogiq Sleep
powered by Muse^®

Muse S Athena is a comfortable, user-friendly EEG wearable that scores full sleep architecture (Wake, N1 to N3, REM) at 88–96% agreement with Level 1 gold-standard polysomnography (PSG). Proven with 16.8+ million sessions across 500,000+ real-world users, 1 billion+ minutes of brain data and 200+ peer-reviewed studies.

Click here to learn more

Assessment Suite

Comprehensive, multi-modal assessments for both in-clinic and at-home measurement of cognition, neurophysiology and behaviour. Grounded in scientific literature, repeatable and engaging, language-agnostic and suitable for deployment at scale globally.

Assessment Suite

AI Powered Analytics

Proprietary machine learning-based methods are used to evaluate the multi-dimensional real-world datasets generated through NeuLogiq. These analytics are designed to support exploratory research analysis, enabling the identification of subtle patterns and changes within datasets to inform research hypotheses and trial insights.

AI Powered Analytics

NeuLogiq LingoX
powered by AcceXible

The only large-scale, decentralised, brief self-administered voice-based cognitive assessment. Taking only 60 seconds, LingoX is sensitive to early pathology and subtle cognitive impairment. Clinically validated across 18+ studies and 15,000 participants. CE-market, backed by patented IP and developed to ISO 13485 standards.

Click here to learn more

LingoX Test

End-to-End
Customer Support

Customer Success approach for the benefit of Sponsors, Sites & Patients. End-to-end operational, technical and scientific support from trial design, through deployment, to analysis.

Customer Support

Leveraging Digital Biomarkers to Generate Real-World Physiological and Behavioral Data in CNS Clinical Studies- featuringCSO Brian Murphy, PhD and CJ Barnum, VP of CNS Development at INmuneBio

WEBINAR

Leveraging Digital Biomarkers to Generate Real-World Physiological and Behavioral Data in CNS Clinical Studies

CJ Barnum
VP of CNS Development at INmuneBio

Tina Sampath
CEO, Cumulus Neuroscience

Brian Murphy, PhD
Co-founder & CSO, Cumulus Neuroscience

Webinar 5 image

WEBINAR

What if your team could capture objective, physiological and behavioral study data from a diverse group of patients on an ongoing basis, from their own home?

CJ Barnum
VP of CNS Development at INmuneBio

Brian Murphy, PhD
Co-founder & CSO, Cumulus Neuroscience

Webinar 4 image

WEBINAR

Case Study: EEG Digital Biomarkers in Neuropsychiatric Clinical Studies

Snezana Milanovic, MD, MSc
Senior Director, Translational Medicine and Early Development, Sumitomo Pharma America, Inc.

Alison Buick, PhD, Global Head of Business Development, Cumulus Neuroscience

Innovations in Alzheimer’s Disease Clinical Trials: Digital Endpoints featuring Ruth McKernan,

WEBINAR

Innovations in Alzheimer’s Disease Clinical Trials: Digital Endpoints

Dr. Ruth McKernan, FMEdSci CBE
Operating Partner, SV Health Investors, CEO, Draig Therapeutics and Chair, Cumulus Neuroscience

Prof. James Rowe, BA BMBCh FRCP PhD
Director of Cambridge Centre for Frontotemporal Dementia and Related Disorders, Department of Clinical Neurosciences, University of Cambridge and Chief Investigator for CNS-101

Bryan Hansen
Director of Innovative Health, Portfolio Launch Excellence, J&J Innovative Medicine Research & Development

Brian Murphy, PhD
Co-Founder & CSO, Cumulus Neuroscience

Webinar 2 image

WEBINAR

Neuropsychiatry Clinical Trials: Evolving with Portable EEG and Digital Endpoints

Aaron Koenig, MD
CMO at Delix Therapeutics

Brian Murphy, PhD
Co-founder & CSO, Cumulus Neuroscience

Alison Buick, PhD
Global Head of Business Development, Cumulus Neuroscience

Learn How we can Support your Clinical Studies